The utility of hyperthermic intra-abdominal chemotherapy with gemcitabine for the inhibition of tumor progression in an experimental model of pancreatic peritoneal carcinomatosis, in relation to their behavior with pancreatic cancer stem cells CD133+ CXCR4+

García-Santos, Esther; Padilla, David; Campos, Pedro Villarejo; Murillo-Lázaro, Cristina; Fernández-Grande, Esther; Palomino-Muñoz, T.J.; Rodríguez‐Martínez, Marta; Amo-Salas, Mariano; Nuñez-Guerrero, Paloma; Sánchez-García, Susana; Puerto-Puerto, Alejandro; Martín-Fernández, Jesús

doi:10.1016/j.pan.2016.04.031

Cited by 9 publications

(7 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While surgical resection is currently the only treatment with a chance of a successful outcome, 80% of cases at the time of diagnosis are inoperable due to extensive metastasis. There are few effective diagnostic methods and treatments for PDAC (2). Therefore, it is an urgent matter to elucidate the molecular mechanisms underlying the development and malignant features of PDAC.…”

Section: Introductionmentioning

confidence: 99%

BACH1 Promotes Pancreatic Cancer Metastasis by Repressing Epithelial Genes and Enhancing Epithelial–Mesenchymal Transition

et al. 2020

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is among the cancers with the poorest prognoses due to its highly malignant features. BTB and CNC homology 1 (BACH1) has been implicated in RAS-driven tumor formation. We focused on the role of BACH1 in PDAC, more than 90% of which have KRAS mutation. Knockdown of BACH1 in PDAC cell lines reduced cell migration and invasion, in part, by increasing E-cadherin expression, whereas its overexpression showed opposite effects. BACH1 directly repressed the expression of FOXA1 that is known to activate the expression of CDH1 encoding E-cadherin and to inhibit epithelial-to-mesenchymal transition. BACH1 also directly repressed the expression of genes important for epithelial cell adhesion including CLDN3 and CLDN4. In a mouse orthotopic implantation model, BACH1 was required for the high metastatic ability of AsPC-1 cells. IHC analysis of clinical specimens with a newly developed anti-BACH1 mAb revealed that high expression of BACH1 is a poor prognostic factor. These results suggest that the gene regulatory network of BACH1 and downstream genes including CDH1 contribute to the malignant features of PDAC by regulating epithelial-tomesenchymal transition.Significance: Greater understanding of the gene regulatory network involved in epithelial-to-mesenchymal transition of pancreatic cancer cells will provide novel therapeutic targets and diagnostic markers.

show abstract

Section: Introductionmentioning

confidence: 99%

BACH1 Promotes Pancreatic Cancer Metastasis by Repressing Epithelial Genes and Enhancing Epithelial–Mesenchymal Transition

et al. 2020

View full text Add to dashboard Cite

show abstract

“…No technical complications were observed during administration. With the development of this model, a significant reduction in pancreatic tumor stem cells CD133 + CXCR4 + and tumor volume was obtained (35).…”

Section: Discussionmentioning

confidence: 99%

“…For the second problem, the increase of abdominal pressure in a HIPEC closed system, our group considered that this morbidity could increase after using CO 2 to create turbulence during HIPEC to achieve better drug distribution. However, we have demonstrated in the experimental models and clinical pilot study that using a closed HIPEC technique with CO 2 recirculation, even with a laparoscopic approach, after performing cytoreductive surgery for peritoneal metastases is possible and safe, with an efficacy equal to that of conventional methods (34)(35)(36)(37)(38)(39)(40).…”

Section: S86mentioning

confidence: 99%

Safety of perioperative hyperthermic intraperitoneal chemotherapy with gemcitabine in patients with resected pancreatic adenocarcinoma: a pilot study of the clinical trial EudraCT 2016-004298-41

Padilla-Valverde¹,

García-Santos²,

Sánchez³

et al. 2021

J Gastrointest Oncol

Self Cite

View full text Add to dashboard Cite

“…GEM has been tested for intraperitoneal use in animal studies [26], showing that immediate or simultaneous intraoperative application of GEM into the abdominal cavity may completely prevent the generation of PC from tumour cells; however, early postoperative locoregional chemotherapy could only reduce the severity of PC. The use of GEM as a HIPEC agent could also effectively reduce the volume of CD133 + CXCR4 + pancreatic cancer stem cells in athymic nude rats [27], and hyperthermia was able to increase GEM cytotoxicity in pancreatic cancer cell line SW1990 cells by inducing apoptosis via the ROS/JNK signalling pathway. In addition, the pharmacokinetics of GEM make it an excellent drug for intraperitoneal use [28].…”

Section: Survival Analysismentioning

confidence: 99%

Efficacy of Hyperthermic Intraperitoneal Chemotherapy Alone for Diffuse Peritoneal Carcinomatosis from Pancreatic Adenocarcinoma: A Single-Centre Retrospective Cohort Study

Liu,

Huang,

Wang

et al. 2024

Preprint

View full text Add to dashboard Cite

Background. Pancreatic ductal adenocarcinoma (PDAC) is associated with poor prognosis, and the median survival of patients with peritoneal carcinomatosis (PC) from PDAC is measured in weeks. Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has been reported to improve survival. Although performing CRS is difficult in most patients with advanced PDAC, the role of HIPEC in patients with diffuse PC from PDAC has not yet been defined. This retrospective single-centre study aimed to evaluate the efficacy of sole HIPEC treatment and to identify principal prognostic indicators in patients with PC from PDAC. Method. The HIPEC group included 316 patients with diffuse PC from PDAC who were treated with HIPEC from January 2016 to October 2022. The standard group included pancreatic PC patients treated with intravenous chemotherapy without HIPEC during the same period. Kaplan–Meier survival curves and multivariate Cox regression models were used for analysis. Results. Median age was 63 years. Median follow-up duration was 6.6 months. Positive prognostic indicators included gender, differentiation of pancreatic cancer, chemotherapy before HIPEC, level of leukocyte counts, albumin level, and the level of serum CA19-9. Conclusion. HIPEC is recommended for those patients with diffuse PC from PDAC and acceptable mortality and morbidity. The prognostic role of serum markers and chemotherapy may be important in advanced PDAC with PC.

show abstract

The utility of hyperthermic intra-abdominal chemotherapy with gemcitabine for the inhibition of tumor progression in an experimental model of pancreatic peritoneal carcinomatosis, in relation to their behavior with pancreatic cancer stem cells CD133+ CXCR4+

Cited by 9 publications

References 33 publications

BACH1 Promotes Pancreatic Cancer Metastasis by Repressing Epithelial Genes and Enhancing Epithelial–Mesenchymal Transition

BACH1 Promotes Pancreatic Cancer Metastasis by Repressing Epithelial Genes and Enhancing Epithelial–Mesenchymal Transition

Safety of perioperative hyperthermic intraperitoneal chemotherapy with gemcitabine in patients with resected pancreatic adenocarcinoma: a pilot study of the clinical trial EudraCT 2016-004298-41

Efficacy of Hyperthermic Intraperitoneal Chemotherapy Alone for Diffuse Peritoneal Carcinomatosis from Pancreatic Adenocarcinoma: A Single-Centre Retrospective Cohort Study

Contact Info

Product

Resources

About